

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2023	2022	2023	2022
Grant and collaboration revenue	\$ -	\$ -	\$ -	\$ 82
Operating expenses:				
Research and development	4,720	1,307	7,539	2,638
General and administrative	1,459	935	2,910	2,114
	<u>6,179</u>	<u>2,242</u>	<u>10,449</u>	<u>4,752</u>
Loss from operations	(6,179)	(2,242)	(10,449)	(4,670)
Interest income	251	-	484	1
Net loss	<u>\$ (5,928)</u>	<u>\$ (2,242)</u>	<u>\$ (9,965)</u>	<u>\$ (4,669)</u>
Loss per common share	<u>\$ (0.22)</u>	<u>\$ (0.18)</u>	<u>\$ (0.38)</u>	<u>\$ (0.47)</u>

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	June 30, 2023	Dec. 31, 2022
Assets:		
Cash and cash equivalents	\$ 17,789	\$ 27,613
Other current assets	2,038	1,326
Total current assets	<u>19,827</u>	<u>28,939</u>
Property and other assets, net	1,422	2,409
Total assets	<u>\$ 21,249</u>	<u>\$ 31,348</u>
Liabilities and stockholders' equity		
Total liabilities	\$ 4,085	\$ 4,748
Stockholders' equity	17,164	26,600
Total liabilities and stockholders' equity	<u>\$ 21,249</u>	<u>\$ 31,348</u>
Common shares outstanding	26,443,649	26,334,953